Application and efficacy evaluation of a modified continuous penetrating-suture pancreaticojejunos-tomy in patients with high risk of clinically relevant postoperative pancreatic fistula
10.3760/cma.j.cn113884-20240222-00052
- VernacularTitle:改良贯穿式胰肠连续吻合术在临床相关术后胰瘘高危胰腺肿瘤患者中的应用及疗效评价
- Author:
Daohai QIAN
1
;
Bin LIU
;
Zhaoxing LI
;
Bin JIANG
;
Shihang XI
;
Zhengchao SHEN
;
Guannan WANG
;
Minghua HU
;
Xiaoming WANG
Author Information
1. 皖南医学院第一附属医院肝胆外科，芜湖 241001
- Keywords:
Pancreas;
Pancreaticojejunostomy;
Treatment outcome;
Postoperative pancreatic fistula
- From:
Chinese Journal of Hepatobiliary Surgery
2024;30(8):592-596
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the efficacy of a modified continuous penetrating-suture pancreaticojejunostomy (PPJ), also known as a continuous PPJ with a U-shaped reinforcement of pancreatic section (U-PPJ), in patients with high risk of clinically relevant postoperative pancreatic fistula (CR-POPF).Methods:Clinical data of 33 patients with pancreatic tumors undergoing pancreatic surgery in the Department of Hepatobiliary Surgery, the First Affiliated Hospital of Wannan Medical College from August 2017 to December 2023 were collected, including 22 males and 11 females, aged (64.9±8.6) years old. According to the fashion of pancreaticojejunostomy, patients were divided into two groups: U-PPJ group ( n=11) and PPJ group ( n=22). The general data, incidence of CR-POPF, abdominal bleeding and other clinicopathological data were collected. Results:All patients underwent pancreatic surgery successfully and were discharged from the hospital uneventfully. Intraoperative blood loss in U-PPJ group was 200.00 (100.0, 200.0) ml, postoperative hospitalization was 13.0 (11.0, 18.0) d, and the drain removal time was 17.0 (12.0, 21.0) d, and no CR-POPF occurred. The intraoperative blood loss, postoperative hospitalization days, drain removal time, and incidence of postoperative biochemical leakage were comparable between the groups (all P>0.05). The incidence of CR-POPF in U-PPJ group was lower than that in PPJ group [0 vs. 22.7% (5/22), P<0.05]. Conclusion:U-PPJ is safe and effective in patients with pancreatic tumors and might reduce the incidence of CR-POPF.
